Study IDs Gene for Late-Onset A... ( Finding could lead to more effective ...)

Study IDs Gene for Late-Onset Alzheimer's

Date:5/28/2008

Finding could lead to more effective drugs to slow progression of disease

WEDNESDAY, May 28 (HealthDay News) -- A gene that plays a role in Alzheimer's disease in two large families in which many siblings suffer from the neurodegenerative condition has been identified by U.S. researchers.

Identification of this gene -- TRPC4AP on chromosome 20 -- opens a new line of research that may help improve understanding of what causes Alzheimer's disease.

TRPC4AP is involved in calcium regulation. It's known that when calcium levels aren't carefully controlled, cells can die, leading to the onset of disease.

In this study, researchers at the Medical College of Georgia and the VA Medical Center in Augusta focused on two large families with a history of late-onset Alzheimer's disease who were enrolled in a DNA bank. Both families had 15 siblings, five of whom had Alzheimer's. Analysis of blood samples revealed that all the patients in both families had the same pattern of single nucleotide polymorphisms (SNPs), which are single base changes in gene structure found throughout DNA.

When they analyzed samples from other Alzheimer's patients in the DNA bank, the researchers found that 36 percent had the same pattern of SNPs as the patients in the two families.

The study was published in the current issue of the American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

"The use of extended pedigrees is vital for genetic studies. The next step will be to identify the exact mutation in this gene which is causing the disease. The DNA is currently being sequenced to find this mutation," study author Dr. Shirley Poduslo said in a prepared statement.

"The long-term significance will be to understand the mechanism of the disease so that more effective drugs can be designed to slow the progression of the disease, delay the onset, identify patients early in the disease course an
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Study: Child maltreatment victims lose 2 years of quality of life
2. New study shows sedentary high school girls are at significant risk for future osteoporosis
3. $1.3M NIH grant to fund Parkinsons disease study
4. New vaccine approach prevents/reverses diabetes in lab study at Childrens Hospital of Pittsburgh
5. New Study of Bush Medicare Cuts: Texas Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation
6. Research Study Shows That Pharmaceutical Field Sales Reps Productivity Inhibited by Unnecessary Internal Communication
7. Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
8. New study reveals brain cell mechanism of alcohol dependence
9. Looking Tired or Angry May Have More to do With Facial Aesthetics Than How You Feel, ASPS Study Reveals
10. Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics
11. Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer

Post Your Comments:

(Date:12/17/2009)... DIEGO, Dec. 17 CareFusion Corporation (NYSE: ... notified of an unsolicited mini-tender offer by TRC Capital ... of CareFusion common stock, representing approximately 1.8 percent of ... of $23.50 per share is 4.62 percent below the ... 14, 2009, the last full trading day prior to ...

(Date:12/17/2009)... John Howell, CEO of Arrayit ... Corporation (OTC Bulletin Board: ARYC), today formally ... of its microarray-based OvaDx(TM) Pre-Symptomatic ... advancing through late-stage development - the rights ... the Company by Arrayit Corporation. ,, Howell ...

(Date:12/17/2009)... December 17 Researchers from the School ... University in the UK are today,encouraging families ... the,New Year following concerning research* that shows two-thirds ... as a family (68%), with the,Portuguese being the ... to,walk together. , According ...

(Date:12/17/2009)... a revealing portrait of the nearly one-in-three American adults who serve ... ... December 17, 2009 -- The National Alliance on Mental Illness (NAMI) ... which offers a revealing portrait of the nearly one-in-three American adults ... based on interviews with 1,480 caregivers chosen at random and offers ...

(Date:12/17/2009)... the past three years and what has driven these changes ... ... the human capital research firm, will host a webinar titled “The ... hour-long webinar will be broadcast on Wednesday, January 27, 2010 at ... SVP, Consulting Services and Trevor Byrd, Ph.D., a Morehead Consultant, as ...

Breaking Medicine News(10 mins):Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2 Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2 Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3 Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4 Health News:The Family Walk - a Dying Tradition Around the World? 2 Health News:NAMI Applauds New Report on Caregiving 2 Health News:NAMI Applauds New Report on Caregiving 3 Health News:Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review" 2

[0] CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital [0] Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 [0] The Family Walk - a Dying Tradition Around the World?[0] NAMI Applauds New Report on Caregiving [0] Morehead Presents Webinar on "The State of Employee Engagement: A Year in Review"

... over 77,000 Votes, St. Jude Children,s Research Hospital(R) Wins ... weeks, St. Jude Children,s Research Hospital(R) tallied 26.6% of ... first-ever Target giving campaign on Facebook(R). Bullseye Gives, ... 25, 2009, invited Facebook users to visit ...

... Creative Therapies to help children with special needsBRADENTON, Fla., ... today announced plans to open a new 9-acre ... in the development of children with special needs. ... Nathanson , the program is thought to be the ...

... be re-evaluated, experts say, , , TUESDAY, May 26 ... better faster, giving acid-suppressing medications to many hospital ... while in the hospital, new research suggests. , ... been shown to prevent serious gastrointestinal problems caused ...

... OVIEDO, Fla., May 26 It,s official. Central Floridians ... Pressure Screenings in a Single Day. The new record 2,075 blood ... on May 23 in Oviedo, FL. In from London was ... verified the record onsite. Country Music star Jake Owen, ...

... ROCHESTER, Minn., May 26 Patients living with ... a positive future. Two review articles and an ... Another Pill," in the current issue of Mayo ... premise."Migraine is a potentially chronic, progressive disease that ...

... Pa., May 26 Pennsylvania is partnering with ... enjoy a healthier and longer life, Secretary of ... Zahorchak announced today.James and Zahorchak visited Albert Gallatin ... to announce two new initiatives aimed at increasing ...

Other Medicine News:Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 2 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 3 Health News:More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities 4 Health News:World's First Animatronic Animal Therapy Program Set to Open 2 Health News:World's First Animatronic Animal Therapy Program Set to Open 3 Health News:Acid-Suppressing Meds May Boost Pneumonia Risks 2 Health News:Acid-Suppressing Meds May Boost Pneumonia Risks 3 Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 2 Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 3 Health News:Pennsylvania Secretaries of Health, Education Announce New Grant Initiatives to Curb Childhood Obesity, Boost Physical Activity in Schools 2

More Than 167,000 Fans Flock to Target Facebook Page Helping Donate $3 Million to Ten Charities World's First Animatronic Animal Therapy Program Set to Open Acid-Suppressing Meds May Boost Pneumonia Risks Singers Mandisa & Jake Owen Help Community Health Organization Set Guinness World Record and Governor's Official Proclamation Declared Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder Pennsylvania Secretaries of Health, Education Announce New Grant Initiatives to Curb Childhood Obesity, Boost Physical Activity in Schools

(Date:12/16/2009)... Dec. 16 TechniScan, Inc. ... a medical device company engaged in the development ... system, announced today that Joe Pepper, PhD, has ... ,, Board Chairman Ken Hungerford commented, "Joe ... devices companies, including GE OEC Medical and U-Systems, ...

(Date:12/16/2009)... -- Naurex Inc., a new clinical stage company ... disorders based on its novel GFPA NMDA receptor ... Phase I clinical trial of its lead compound ... in the study. GLYX-13, a glycine site ... NMDA receptor, is initially being developed as a ...

(Date:12/16/2009)... 16 The Boards of Silence Therapeutics ... to announce the merger of their businesses to ... RNAi (RNA interference). The enlarged company, to ... discovery, development and delivery technologies, a broad internal ... of intellectual property. ,, The Directors believe ...

Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2 In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2 Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3 Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 2 Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 3 Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 4 Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 5 Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company 6 ARUP Laboratories Announces New CMO Appointment 50826 1 ARUP Laboratories Announces New CMO Appointment 50826 2 Despite More Tests Some Arent Getting Results 50822 1 Despite More Tests Some Arent Getting Results 50822 2 Despite More Tests Some Arent Getting Results 50822 3 Antidepressants aid electroconvulsive therapy in treating severe depression 50818 1 Antidepressants aid electroconvulsive therapy in treating severe depression 50818 2

[0] In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors [0] Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression [0] Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company

... Reported Unlike What Is Commonly Seen In,Insulin Therapy, ... announced results of a new study that further ... detemir,[rDNA origin] injection). Patients with type 2 diabetes ... and achieve improvements,in blood sugar, comparable to dosing ...

... of DG041 as an,effective anti-platelet that does ... 25, 2007 /PRNewswire-FirstCall/ --,deCODE genetics today announced ... Phase II developmental compound for the,prevention of ... IIa and,clinical pharmacology studies presented today build ...

Other Medicine Technology:New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 2 New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 3 New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 4 New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir 5 Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 2 Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 3 Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 4 Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 5 Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event 6

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event

VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...

The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...

Medicine Products:

VascoScrew P 6/60 S VascoScrew E 8/60 S VascoScrew E 6/60 S VascoScrew E 5/60 PU S

Study IDs Gene for Late-Onset A...( Finding could lead to more effective ...),Health